-
REAL-WORLD EFFECTIVENESS OF STATIN THERAPY AND PREDICTIVE MODELING OF ADHERENCE AMONG PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA
Mar 18, 2026, 21:38 PM -
FAMILY IMPACT OF ADULT ANGELMAN SYNDROME: CAREGIVER PERSPECTIVES
Mar 18, 2026, 21:38 PM -
EFFECTIVENESS OF A CENTRALIZED COMMUNITY PHARMACY-BASED PATIENT ACCESS AND THERAPY MANAGEMENT PROGRAM FOR SPECIALTY-LITE MEDICATIONS: A NATIONAL REAL-WORLD STUDY
Mar 18, 2026, 21:38 PM -
EFFICACY AND EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITORS IN TRIPLE-NEGATIVE BREAST CANCER: A SYSTEMATIC LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
FROM DATA TO INSIGHTS: VALIDATING ARTIFICIAL INTELLIGENCE (AI)-GENERATED WRITING IN EVIDENCE SYNTHESIS
Mar 18, 2026, 21:38 PM -
A REVIEW ON THE APPLICATION OF PATIENT-REPORTED OUTCOMES IN THE LABELING OF NEW ONCOLOGY DRUGS
Mar 18, 2026, 21:38 PM -
CHARACTERIZING GLOBAL ISPOR STUDENT PARTICIPATION: A NORTH AMERICA VS. REST OF WORLD COMPARISON
Mar 18, 2026, 21:38 PM -
IMPACT OF A DIGITAL CARDIOVASCULAR MANAGEMENT PROGRAM ON HEALTHCARE COSTS AND UTILIZATION IN PATIENTS WITH HEART FAILURE: A PROPENSITY-MATCHED COHORT ANALYSIS
Mar 18, 2026, 21:38 PM -
PREVALENCE AND HEALTHCARE BURDEN OF COMPLICATED URINARY TRACT INFECTIONS AMONG HOSPITALIZED PATIENTS IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
PROJECTED IMPACT OF PERSONALIZED MRNA NEOANTIGEN CANCER VACCINES IN MEDICARE: A SCENARIO ANALYSIS USING TRIAL EFFICACY AND LINKED DATA POPULATION ESTIMATES
Mar 18, 2026, 21:38 PM -
REAL-WORLD COST-EFFECTIVENESS AND OPPORTUNITY COSTS OF ANTI-IL-17/23 VERSUS ANTI-TNF? THERAPIES FOR PSORIASIS USING DLQI
Mar 18, 2026, 21:38 PM -
UNRAVELING THE MULTILEVEL FACTORS INFLUENCING TRANSITION TO RADICAL TREATMENT IN MEDICARE BENEFICIARIES NEWLY DIAGNOSED WITH LOW-RISK AND FAVORABLE INTERMEDIATE-RISK PROSTATE CANCER INITIATING ACTIVE SURVEILLANCE: A FINE-GRAY AND CAUSE-SPECIFIC...
Mar 18, 2026, 21:38 PM -
HEALTH-RELATED QUALITY OF LIFE AND MAPPED HEALTH UTILITY VALUES OF PATIENTS WITH ANKYLOSING SPONDYLITIS IN CHINA: A MULTICENTER REAL-WORLD STUDY
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF AMIVANTAMAB PLUS LAZERTINIB FOR FIRST-LINE TREATMENT OF EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER: A U.S. PAYER PERSPECTIVE
Mar 18, 2026, 21:38 PM -
RACIAL, ETHNIC, AND SOCIOECONOMIC DISPARITIES IN P2Y12 INHIBITOR PRESCRIBING FOLLOWING PCI IN MEDICARE BENEFICIARIES
Mar 18, 2026, 21:38 PM -
AUTHOR
Mar 18, 2026, 21:38 PM -
SOCIAL AND STRUCTURAL DETERMINANTS OF BUPRENORPHINE ADHERENCE AMONG INDIVIDUALS WITH OPIOID USE DISORDER
Mar 18, 2026, 21:38 PM -
THE COST OF INEQUITY: ESTIMATING THE IMPACT OF DELAYED ACCESS TO NEOADJUVANT PERTUZUMAB IN CANADA
Mar 18, 2026, 21:38 PM -
QUALITY FIRST: MODERNIZING THE NURSING CURRICULUM FOR ACCREDITED HEALTHCARE
Mar 18, 2026, 21:38 PM -
COST-CONSEQUENCE ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN COLOMBIA
Mar 18, 2026, 21:38 PM
